The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha mice.
This study examined the effect of mixed bacterial vaccine (MBV), a biological response modifier prepared from Streptococcus pyogenes and Serratia marcescens, on the immune system of mice and on the regression of a transplantable mouse tumor sarcoma 37. The study examined MBV's biological properties and analyzed its chemical composition. The chemical composition varied with the growth media. A typical centrifuged, dialyzed supernate of the serum-containing preparation was found to consist mainly of protein and minimal amounts of carbohydrate and endotoxin, while MBV made with synthetic medium contained similar amounts of all three. MBV was nontoxic for mice, which gained weight following the injection of 0.5-1.0 ml of MBV. MBV caused regression of 20-100% of well-established mouse tumors without appreciable toxicity. MBV also had a striking effect on the immune response of mice to sheep red blood cells. When administered simultaneously with antigen injection, MBV increased the number of antibody-secreting splenocytes measured by the plaque-forming assay threefold. Serum antibody levels also increased two- to threefold. MBV did not enhance the immune response to pneumococcal polysaccharide type III, a B-cell-dependent response. However, the in vivo administration of MBV increased the in vitro response to MBV and the B-cell mitogen lipopolysaccharide. MBV compares favorably with other biological response modifiers because of its enhancing effect on the immune response and its oncolytic properties at nontoxic levels.
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
H F
HF
Havas
G
G
Schiffman
B
B
Bushnell
M
M
Dellaria
R S
RS
Axelrod
T
T
Shanahan
M M
MM
Burns
C F
CF
Guan
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D002241:Carbohydrates / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D004731:Endotoxins / Q000032:analysis; D006462:Hemolytic Plaque Technique; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008813:Mice, Inbred ICR; D008934:Mitogens / Q000494:pharmacology; D009368:Neoplasm Transplantation; D011506:Proteins / Q000032:analysis; D012511:Sarcoma 37 / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000628:therapy*; D012706:Serratia marcescens / Q000276:immunology*; D013297:Streptococcus pyogenes / Q000276:immunology*
D001428:Bacterial Vaccines; D002241:Carbohydrates; D004731:Endotoxins; D008934:Mitogens; D011506:Proteins; D003520:Cyclophosphamide